SutroVax Finds $64M For Pneumococcal Vaccines
Foster City-based SutroVax, a company developing pneumococcal conjugate vaccines, announced on Tuesday that it has raised $60M in a Series B funding round. The funding was led by Frazier Healthcare Partners and Pivotal bioVenture Partners, plus Abingworth, Longitude Capital, Roche Venture Fund and CTI Life Sciences Fund. The company said it has also raised an additional, $4M in funding from its existing investors, separate from the Series B. SutroVax is developing a vaccine aimed at preventing invasive pneumococcal disease caused by Streptococcus pneumoniae. SutroVax is led by CEO Grant Pickering.
posted on Tuesday, March 21, 2017 (Link to more information)
Related companies:
SutroVax
Related stories:
> SutroVax Finds $22M
> Meissa Vaccines Finds Funding
> Juvaris BioTherapeutics Finds $25M
> Vaxart Gets $12.5M For Oral Vaccines
> Vaxart Gets $3.5M
silicontap.com Home